CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

← catalyst calendar

NCT06927648 · readout in 1,229 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

130estimated

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-10-15

actual

When the study began enrolling

Primary completion

2029-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-12-30

estimated

The whole study's end, after follow-up

First posted

2025-04-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Breast Cancer

Primary outcome

what the primary-completion date above is the date OF

Adverse Events (AEs)·Adverse Drug Reactions (ADRs) Serious Adverse Events (SAEs)·Adverse Drug Reactions (SADRs) Unexpected Adverse Events (AEs)·Adverse Drug Reactions (ADRs)

measured For about 12 months from the first dose of the study drug unless they withdraw consent, are lost to follow-up, experience disease progression, or die. 30 days addtional follow up in case of not completing 12 months.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed